Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

Hannah Choi; Grishma Hirode; Chien‐Hung Chen; Tung‐Hung Su; Wai‐Kay Seto; Stijn Van Hees; Μargarita Papatheodoridi; Sabela Lens; Grace Lai–Hung Wong; Sylvia M. Brakenhoff; Rong‐Nan Chien; Jordan J. Feld; Milan J. Sonneveld; Henry Lik‐Yuen Chan; Xavier Forns; George Papatheodoridis; Thomas Vanwolleghem; Man‐Fung Yuen; Yao‐Chun Hsu; Jia‐Horng Kao; Markus Cornberg; Bettina E. Hansen; Wen‐Juei Jeng; Harry L.A. Janssen

doi:10.1016/j.cgh.2022.07.005

Abstract

This is the authors' abstract. We don't add key points for this paper.

TDF and ETV have differential relapse patterns but are associated with similar rates of HBsAg loss and retreatment following discontinuation. Finite therapy can be considered for CHB patients on either TDF or ETV therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Choi et al. (2022) studied this question.

synapsesocial.com/papers/69d74082a863640d1fb8a338 https://doi.org/10.1016/j.cgh.2022.07.005

View Full Paper

Ask AI

Bookmark

Share

Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

Abstract

Discussion

Cite This Study

Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B

Abstract

Discussion

Cite This Study

Keep reading

Keep reading